Patients with interstitial lung disease can develop a progressive fibrosing phenotype
characterised by an irreversible, progressive decline in lung function despite treatment …

Introduction The two available therapies for idiopathic pulmonary fibrosis (IPF), pirfenidone
and nintedanib, slow down but do not halt IPF progression. Therefore, several agents with …

Introduction There is an unmet need for new treatments for idiopathic pulmonary fibrosis
(IPF). The oral preferential phosphodiesterase 4B inhibitor, BI 1015550, prevented a decline …

Background and Purpose The PDE4 family is considered a prime target for therapeutic
intervention in several fibro‐inflammatory diseases. We have investigated the molecular …

Phosphodiesterase enzymes (PDE) have long been known as regulators of cAMP and
cGMP, second messengers involved in various signaling pathways and expressed in a …

特发性肺纤维化(IPF) 是一种进行性并最终致命的慢性间质性肺病, 其特征是肺功能进行性下降,
且目前治疗选择有限. cAMP 是最重要的第二信使之一, 在松弛气道平滑肌细胞和减少炎症方面 …

Idiopathic pulmonary fibrosis is a progressive lung disease of unknown etiology,
characterized by the replacement of normal lung tissue with connective tissue that does not …

Zusammenfassung Bei der Betreuung von Patienten mit interstitiellen Lungenerkrankungen
(ILDs) steht aktuell eine breite Auswahl an medikamentösen Therapieoptionen zur …

Patients with autoimmune diseaserelated interstitial lung disease may develop pulmonary
fibrosis, which may become progressive. Progressive pulmonary fibrosis (PPF) is associated …

Idiopathic pulmonary fibrosis (IPF) is a progressive and ultimately fatal chronic interstitial
lung disease characterized by a progressive decline in lung function, and current treatment …